Pyroxidine for the Palmar-Plantar Erythrodysesthesia Syndrome
Authors: Svetislava J. Vukelja
Journal: Annals of Internal Medicine (1989)

Letters and Corrections15 October 1989Pyroxidine for the Palmar-Plantar Erythrodysesthesia SyndromeSvetislava J. Vukelja, MD, Fredric A. Lombardo, PharmD, William D. James, MD, Raymond B. Weiss, MDSvetislava J. Vukelja, MDSearch for more papers by this author, Fredric A. Lombardo, PharmDSearch for more papers by this author, William D. James, MDSearch for more papers by this author, Raymond B. Weiss, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-8-688 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Reported cutaneous reactions associated with 5-fluorouracil seem to depend on dose and schedule (1). The palmar-plantar erythrodysesthesia syndrome (PPES) was initially described in patients receiving continuous infusions of 5-fluorouracil for as long as 30 days, and recently Bellmunt and colleagues (2) reported the syndrome in patients on a 5-day continuous infusion schedule of 5-fluorouracil. However, PPES has also been reported in a patient receiving weekly bolus 5-fluorouracil (3). We report a second case of the syndrome in a patient receiving weekly bolus 5-fluorouracil and emphasize an effective treatment for this problem.A 63-year-old man with metastatic pancreatic...References1. LokichMoore JC. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1984;101:798-800. LinkGoogle Scholar2. BellmuntNavarroHidalgoSole JMRL. Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. Tumori. 1988;74:329-31. CrossrefMedlineGoogle Scholar3. Atkins J. Fluorouracil and the plamar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1985;102:419. LinkGoogle Scholar4. GoldmanBraman AS. Isoniazid: a review with emphasis on adverse effects. Chest. 1972;62:71-7. CrossrefMedlineGoogle Scholar5. MolinaFabianSlavikDahlberg RCMS. Reversal of palmar-plantar erythrodysesthesia (PPE) by B6 without loss of response in colon cancer patients receiving 200 mg/m2/day continuous 5-FU [Abstract]. Proc Am Soc Clin Oncol. 1987;6:90. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Walter Reed Army Medical Center Washington, D.C. 20307-5001 Uniformed Services University of the Health Sciences Bethesda, MD 20892 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrug eruptions associated with tumor therapy: Great imitatorsA randomized phase II study evaluating pyridoxine for the prevention of hand–foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancerCutaneous toxicity of oral low-dose methotrexateClinical evidence of prevention strategies for capecitabine-induced hand-foot syndromeIncidence and implications of chemotherapy related hand-foot syndromeFluorouracilAn exploratory study to identify risk factors for the development of capecitabine-induced Palmar Plantar Erythrodysesthesia (PPE)Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysisPyridoxine for Prevention of Hand-Foot Syndrome Caused by Chemotherapy: A Systematic ReviewA randomised study evaluating the use of pyridoxine to avoid capecitabine dose modificationsPyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled StudyDrug ReactionsDRUGS USED IN CANCER CHEMOTHERAPYSearch for Evidence‐Based Approaches for the Prevention and Palliation of Hand–Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant ChemotherapyEritema acral inducido por quimioterapiaAlopecia and Cutaneous ComplicationsChemotherapy-Induced Acral Erythema: A Clinical and Histopathologic Study of 44 CasesCHEMOTHERAPY-INDUCED ACRAL ERYTHEMA IN A PEDIATRIC PATIENT WITH ACUTE MONOBLASTIC LEUKEMIAAcral Erythema with Oral Methotrexate in a ChildPalmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centreTroxacitabine in acute leukemiaTroxacitabine in leukemiaManagement of hand-foot syndrome induced by capecitabinePalmar–plantar erythrodysesthesia due to docetaxel–capecitabine therapy is treated with vitamin E without dose reductionSmall-Fiber Neuropathy Associated with Capecitabine (Xeloda)-induced Hand-foot Syndrome: A Case ReportDermatologic Toxicity of Chemotherapeutic AgentsVascular Toxicity of Antineoplastic AgentsFluorouracilChemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome: Etiology and Emerging TherapiesManagement of hand-foot syndrome in patients treated with capecitabine (Xeloda®)Clinical Phase II Study of Pegylated Liposomal Doxorubicin as Second-Line Treatment in Disseminated MelanomaPalmar-plantar erythrodysesthesiaTroxacitabine-based therapy of refractory leukemiaBullous Acral Erythema Secondary to High-Dose MethotrexateIncidence and Severity of Hand–Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution ExperienceThe clinical pharmacology of the oral fluoropyrimidinesPegylated Liposomal Doxorubicin: Tolerability and ToxicityTroxacitabine, A Novel Dioxolane Nucleoside Analog, Has Activity in Patients With Advanced LeukemiaManagement of Chemotherapy- Induced Adverse Effects in the Treatment of Colorectal CancerPalmar-Plantar Erythrodysesthesia Syndrome Associated with Liposomal DaunorubicinRandomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastasesCytostatic drugsPyridoxine for Hand–Foot SyndromeMucocutaneous reactions to chemotherapyRelationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogsHigh-Dose Taxol, Cyclophosphamide, and Cisplatin with Stem Cell Support in the Treatment of Metastatic Breast CancerTreatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: A Mid-Atlantic Oncology Program studyPalmar-Plantar Erythrodysaesthesia Syndrome Due to 5-Fluorouracil Therapy–An Underestimated Toxic Event?Suspected drug eruption in seven dogs during administration of flucytosineInflammation of solar keratoses following systemic 5-fluorouracilThree Cases of Chemotherapy-induced Acral ErythemaDermatological Toxicity from Chemotherapy Containing 5-FluorouracilUnusual serpentine hyperpigmentation associated with 5-fluorouracilChemotherapy-induced acral erythemaCorrection: Spelling of "Pyridoxine" 15 October 1989Volume 111, Issue 8Page: 688-689 Issue Published: 15 October 1989 PDF downloadLoading ...